• 1
    Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J. Urol. 1998; 159: 18627.
  • 2
    Parsons CL. Prostatitis, interstitial cystitis, chronic pelvic pain, and urethral syndrome share a common pathophysiology: lower urinary dysfunctional epithelium and potassium recycling. Urology 2003; 62: 97682.
  • 3
    Parsons CL, Bautista SL, Stein PC, Zupkas P. Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. J. Urol. 2000; 164: 13814.
  • 4
    Chuang YC, Chancellor MB, Seki S et al. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology 2003; 61: 66470.
  • 5
    Lilly JD, Parsons CL. Bladder surface glycosaminoglycans as a human epithelial permeability barrier. Surg. Gynecol. Obstet. 1990; 171: 4936.
  • 6
    Parsons CL, Dell J, Stanford EJ et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology 2002; 60: 5738.
  • 7
    Riss TL, Moravec RA. Comparison of MTT, XTT and a novel tetrazolium compound MTS for in-vitro proliferation and chemosensitivity assays. Mol. Biol. Cell 1992; 3 (Suppl. 1): 18490.
  • 8
    Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991; 3: 20712.
  • 9
    Keay SK, Szekely Z, Conrads TP et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc. Natl Acad. Sci. USA 2004; 101: 11 803–8.
  • 10
    Erickson DR. Urine markers of interstitial cystitis. Urology 2001; 57 (6 Suppl. 1): 1521.
  • 11
    Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to prospectively study interstitial cystitis and which demonstrates the efficacy of pentosanpolysulfate. J. Urol. 1993; 150: 8458.
  • 12
    Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology 1990; 35: 5528.
  • 13
    Parsons CL, Mulholland SG. Successful therapy of interstitial cystitis with pentosanpolysulfate. J. Urol. 1987; 138: 51316.
  • 14
    Holm-Bentzen M, Jacobsen F, Nerstrom B et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J. Urol. 1987; 138: 5037.
  • 15
    Hanno PM. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997; 49 (Suppl. 5A): 939.
  • 16
    Elmiron® (Pentosan Polysulfate Sodium Capsules) Prescribing Information. Alza Pharmaceuticals, Mountain View, CA, 1998.
  • 17
    Parsons CL. Epithelial coating techniques in the treatment of interstitial cystitis. Urology 1997; 49 (Suppl. 5A): 1004.
  • 18
    Tamm I, Horsfall FL. Characterization and separation of an inhibitor of viral haemagglutination present in urine. Proc. Soc. Exp. Biol. Med. 1950; 74: 10814.
  • 19
    Akiyama A, Stein PC, Houshiar A, Parsons CL. Urothelial cytoprotective activity of Tamm-Horsfall protein isolated from the urine of healthy subjects and patients with interstitial cystitis. Int. J. Urol. 2000; 7: 17683.